Title:Effects of Teriparatide Versus Salmon Calcitonin Therapy for the Treatment of Osteoporosis in Asia: A Meta-analysis of Randomized Controlled Trials
VOLUME: 21 ISSUE: 5
Author(s):Changjun Chen, Mohammed Alqwbani, Jie Zhao, Ruitong Yang, Songgang Wang* and Xin Pan*
Affiliation:Department of Orthopaedics, Shandong University Qilu Hospital, No.107, Jinan Culture Road, Jinan 250012, Department of Orthopaedics Surgery, West China Hospital, Sichuan University, No. 37 Wainan Guoxue Road, Chengdu, 610041, Department of Ophtalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Department of Orthopaedics, Shandong University Qilu Hospital, No.107, Jinan culture road, Jinan 250012, Department of Orthopaedics, Shandong University Qilu Hospital, No.107, Jinan culture road, Jinan 250012, Department of Orthopaedics, Shandong University Qilu Hospital, No.107, Jinan culture road, Jinan 250012
Keywords:Teriparatide, salmon calcitonin, meta-analysis, osteoporosis, Asia, fractures.
Abstract:Objective: The objective of this meta-analysis was to compare the efficacy and safety of
teriparatide versus salmon calcitonin for the treatment of osteoporosis in Asian patients and to investigate
whether the results of global studies could be applicable to Asian patients.
Methods: PubMed, OVID, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE
up to December 2018 were searched. Eligible randomized controlled trials (RCTs) that compared teriparatide
versus salmon calcitonin in Asian osteoporosis population were included. Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for data synthesis,
and Cochrane Collaboration software Review Manager 5.3 was used to analyze the pooled data.
Results: Three RCTs involving 529 patients were included (mean age 68.7 yr; 93.4% females; mean
follow-up 6 months); outcome measures included bone mineral density (BMD) of the femoral neck,
total hip and lumbar spine; bone markers and adverse events. We found that the period of 6-months of
teriparatide treatment was helpful for the improvement of the BMD of lumbar vertebra, however, the
improvement of BMD was not significant in the femoral neck and total hip joint. There was a positive
correlation between bone-specific alkaline phosphatase (BSAP) and osteocalcin (OCN) and the response
of Asian patients to subcutaneous injection of 20 micrograms per day of teriparatide. The proportion
of the occurrence of adverse effects was more obvious in the teriparatide group compared with
salmon calcitonin, but there was no significant difference.
Conclusion: Results suggested that the use of teriparatide could improve the lumbar BMD by shortterm
(six months) application in Asian osteoporosis patients, which is beneficial to the patients who
cannot tolerate adverse events of long-term treatment. The BSAP and OCN bone markers could be
useful to monitor the responses of Asian osteoporosis patients to teriparatide treatment. Finally, both of
teriparatide and salmon calcitonin were well tolerated by Asian patients.
